Skip to main content

Table 1 SBRT fractionations for NSCLC with clinical outcome and calculated TCP for the 20% hypoxic tumour (Figure 1 i)

From: Treatment fractionation for stereotactic radiotherapy of lung tumours: a modelling study of the influence of chronic and acute hypoxia on tumour control probability

Reference

Dose scheme

Total dose (Gy)

Dose prescr.

Treatment outcome

TCP for LQ (USC)

 

Overall survival

Local control

No LOC

LOC

Hof et al. 2007[3] (Germany)

26 Gy × 1

26

Isocenter

74.5% at 1 yeara, 65.4% at 2 yearsa, 37.4% at 3 yearsa

100% at 1 yearb, 72% at ≥ 2 yearsb

0% (0%)

N/A

Fritz et al. 2008[4] (Germany)

30 Gy × 1

30

Isocenter

66% at 2 years, 53% at 3 years

81% at 3 years

0% (0%)

N/A

Zimmermann et al. 2005[5](Germany 65% isodose)

12.5 Gy × 3

37.5

60%

80% at 1 yearc, 75% at 2 yearsc

100% at 1 yearc, 87% at 2 yearsc

7% (4%)

99% (98%)

Baumann et al. 2009[6] (Sweden)

15 Gy × 3

45

67%

86% at 1 year, 65% at 2 years, 60% at 3 years

92% at 3 years

56% (44%)

100% (99%)

Olsen et al. 2011[7] (USA, The Netherlands)

18 Gy × 3

54

80%

92/81% at 1 yeard, 85/61% at 2 yearsd

99% at 1 yeard, 91% at 2 yearsd

62% (50%)

100% (100%)

Haasbeek et al. 2010[8] (The Netherlands)

20 Gy × 3

60

80%

85.7% at 1 yeare, 54% at 2 yearse, 45.1% at 3 yearse

89% at 3 yearse

96% (92%)

100% (100%)

Takeda et al. 2009[9] (Canada)

10 Gy × 5

50

80%

90/63% at 3 years, (Stage 1A/1B)

93/96% at 3 years, (Stage 1A/1B)

0% (0%)

98% (98%)

Haasbeek et al. 2010[8] (The Netherlands)

12 Gy × 5

60

80%

85.7% at 1 yeare, 54% at 2 yearse, 45.1% at 3 yearse

89% at 3 yearse

29% (28%)

100% (100%)

Haasbeek et al. 2010[8] (The Netherlands)

7.5 Gy × 8

60

80%

85.7% at 1 yeare, 54% at 2 yearse, 45.1% at 3 yearse

89% at 3 yearse

0% (0%)

100% (100%)

  1. aBased on doses 19–30 Gy to isocenter: 19 Gy (1 patient), 22 Gy (2), 24 Gy (7), 26 Gy (14), 28 Gy (10), 30 Gy (30).
  2. bPatients receiving 26–30 Gy.
  3. cDose range 24–40 Gy, 69% was given 37.5 Gy, (2 patients had doses prescribed to 80% isodose).
  4. dDoses prescribed to 60-90% isodose (median 84%), overall survival expressed as operable/inoperable patients and including other dose schemes.
  5. eBased on 60 Gy total doses given in 3, 5 and 8 fractions: 3 × 20 Gy (33%), 5 × 12 Gy (50%), 8 × 7.5 Gy (17%).
  6. N/A = Not Applicable.